EyePoint (EYPT) Long-Term Deferred Tax (2017 - 2018)
EyePoint (EYPT) posted Long-Term Deferred Tax of $6.2 million for Q2 2018, down 71.16% sequentially from $21.5 million in Q4 2017, and down 80.32% YoY from $31.5 million in Q2 2017.
EyePoint (EYPT) Long-Term Deferred Tax (2017 - 2018) Analysis & Trends
EyePoint has reported Long-Term Deferred Tax for 2 years, with the latest figure at $6.2 million in Q2 2018.
- Quarterly Long-Term Deferred Tax fell 80.32% year-over-year to $6.2 million in Q2 2018, while the trailing twelve-month figure through Jun 2018 was $6.2 million (down 80.32% YoY) and the FY2018 annual result came in at $6.2 million, down 80.32% from the prior year.
- Long-Term Deferred Tax eased to $6.2 million in Q2 2018 per EYPT's latest filing, from $21.5 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $31.5 million in Q2 2017 and troughed at $6.2 million in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 6.20 Mn |
| Dec 31, 2017 | 21.50 Mn |
| Jun 30, 2017 | 31.50 Mn |